Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Consensus Rating of “Hold” by Analysts

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) have earned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $38.3333.

A number of research firms have issued reports on PHAR. Canaccord Genuity Group began coverage on shares of Pharming Group in a research report on Friday, April 10th. They issued a “buy” rating and a $37.00 price objective on the stock. Oppenheimer restated an “outperform” rating and issued a $41.00 price objective (down from $42.00) on shares of Pharming Group in a research report on Friday, March 13th. Weiss Ratings cut shares of Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. HC Wainwright restated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, March 24th. Finally, Wall Street Zen cut shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th.

Institutional Investors Weigh In On Pharming Group

Several hedge funds have recently bought and sold shares of PHAR. NewEdge Advisors LLC lifted its position in Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares during the period. Millennium Management LLC bought a new position in Pharming Group during the fourth quarter valued at approximately $360,000. SmartHarvest Portfolios LLC bought a new position in Pharming Group during the fourth quarter valued at approximately $224,000. Finally, EverSource Wealth Advisors LLC bought a new position in Pharming Group during the second quarter valued at approximately $32,000. Institutional investors own 0.03% of the company’s stock.

Pharming Group Stock Up 1.2%

PHAR opened at $12.62 on Friday. The company has a 50 day moving average of $15.05 and a 200 day moving average of $16.31. The company has a market cap of $890.87 million, a PE ratio of 78.85 and a beta of -0.04. Pharming Group has a 12 month low of $9.54 and a 12 month high of $21.34. The company has a current ratio of 2.63, a quick ratio of 2.06 and a debt-to-equity ratio of 0.35.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.12). Pharming Group had a return on equity of 4.64% and a net margin of 3.30%.The firm had revenue of $72.45 million during the quarter, compared to the consensus estimate of $92.06 million. On average, sell-side analysts expect that Pharming Group will post 0.6 EPS for the current year.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.